Trial Profile
A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAS-102 in Patients With Advanced Solid Tumors and Varying Degrees of Renal Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Dec 2021
Price :
$35
*
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Taiho Pharmaceutical
- 15 Jun 2021 Status changed from active, no longer recruiting to completed.
- 14 Dec 2020 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.
- 14 Dec 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2021.